TORONTO, ONTARIO--(Marketwire - October 29, 2008) - OccuLogix, Inc. (NASDAQ: OCCXD)(TSX: OC) announced today that its subsidiary, OcuSense, Inc., has submitted its 510(k) premarket notification to the US Food and Drug Administration (the FDA) for clearance to market the TearLab™ Osmolarity System and the TearLab™ Osmolarity Test Card in the United States.
